qtr-two adjusted earnings per share $num-two.
qtr-one sales $num-one million versus refinitiv ibes estimate of $715.8 million.
qtr-one sales fell num-three percent to num-one point num-two million.
qtr-one sales fell num-three percent to $num-two million.
qtrly adjusted eva da decreased by approximately $num-one million as tissue business are lower orders and shipments reflecting overall market trends.
sees year-six capital expenditures of between $num-one million and $2.0 billion.
qtr-one earnings per share $num-one.
qtrly total tissue dollar sales decreased num-one% versus qtr-one year-five.
expect long-term consumption growth to continue between one to num-one% per year.
compname announces num-txt target leverage ratio of num-one.
qtrly private brands issue share in us increased to over num-one% from num-two% in year-five.
sees fy capital expenditures of $num-three million to $4.0 billion.
qtrly tissue demand is expected to weaken further from qtr-one shipments of num-one point num-two million cases.
qtr-two production is expected to exceed num-one% of peak demonstrated production of num-two point num-three million cases in second quarter of year-five.
sees fy year-six adjusted earnings per share $num-one to $3.00.
compname reports qtr-three year-six results; reaffirms num-one% year-five guidance.
